Skip to main content

Table 3 Cross-sectional studies in populations including sporadic Alzheimer's disease patients

From: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

      Values in AD patients  
Study Subjects Mean age (years) Platform and antibodies CV 1-40 1-42 1-42/Aβ1-40 Other
Mehta et al. 2000 [55] 61 CN
78 AD
67
74
ELISA 6E10
R162
R164
<18% = -  
Mayeux et al. 2003 [27] 79 AD
365 CN
83.2 75.5 ELISA 6E10
R182
R165
- = NA  
Fukumoto et al. 2003 [26] 92 CN
96 PD
37 MCI
146 AD
69
66.0 72.6
76
ELISA Takeda <10% = = =  
Assini et al. 2004 [41] 72 CN
88 MCI
73
75
ELISA IBL - - - - Increased Aβ1-42 in MCI women
Lewczuk et al. 2010 [56] 137 MCIp
62 MCI-OD 127 AD
25 OD
67.4 63.3 70.8 66.6 xMAP INNO-BIA <10% - - - MCI and AD with AD-like CSF ↓ Aβ1-42 & ↓ Aβ1-42/1-40
Lui et al. 2010 [14] 724 CN
122 MCI
186 AD
70.0 75.9 78.6 ELISA Mehta xMAP INNO-BIA - = =  
Le Bastard et al. 2010 [12] 47 CN
50 non-AD
47 AD
69
74
82
xMAP INNO-BIA <10% = = = ↓ Aβ1-42/N-42
Toledo et al. 2011 [10], Figurski et al. 2012 [48] 187 CNs
10 CNp
162 MCIs
145 MCIp
162 AD
75.8 78.4 74.7 74.6 75.3 xMAP INNO-BIA <10% = = = Interaction between age and diagnosis defined by CSF
  1. AD, Alzheimer's disease; CN, cognitively normal; CNp, cognitively normal progression; CNs, cognitive normal stable; CV, coefficient of variation; MCI, mild cognitive impairment; MCI-OD, mild cognitive impairment, progression to non-AD dementia; MCIp, mild cognitive impairment progressor (to AD); MCIs, mild cognitive impairment stable; NA, not available; OD, other dementia; PD, Parkinson's disease.